Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.73%
#6 Talus Network Talus Network +20.44%
#7 Wrapped Krown Wrapped Krown +20.00%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.04%
#10 eCash eCash +13.30%
Coin of the day
DeFiChain DeFiChain
設定
言語
日本
通貨
USD
テーマ
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
株式のランク #16315
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
株価
$0.94180721
時価総額
$22.26M
変化（1日）
0.38%
変化（1年）
-14.35%
国
FR
取引 Valbiotis SA (ALVAL)

カテゴリー

Healthcare
Valbiotis SA（ALVAL）の株式分割履歴
Valbiotis SA株（シンボル：ALVAL）は合計で0回の株式分割を実施しました。
最新の株式分割はJul 15, 2026に行われました。
Jul 15, 2026より前に購入されたALVAL株は、現在0ALVAL株に相当します。
株式分割一覧
年 株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5 x199
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 0 -
US
UCB SA UCB SA
UCB SA
UCB.BR
 0 -
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL